Core Viewpoint - Mirxes, JingTai Technology, and Sigmar BioScience are collaborating to establish an AI-driven comprehensive system for early screening, diagnosis, and treatment of gastric cancer, aiming to enhance the accessibility and effectiveness of gastric cancer care in Asia [1][2]. Group 1: Collaboration and Strategy - The three companies will form a joint venture in China and Singapore to leverage their respective strengths in expanding the Asian market [1]. - JingTai Technology will participate as a strategic investor in Mirxes' new stock placement and will engage in deep technical cooperation [2]. Group 2: Technological and Medical Goals - The initiative aims to build a complete treatment cycle for gastric cancer over the next five years, focusing on early screening, diagnosis, and treatment [1]. - The project seeks to systematically reduce the burden of gastric cancer on patients and healthcare systems in China by 2031, addressing the high incidence and mortality rates associated with the disease [1]. Group 3: Market Context - Gastric cancer is a prevalent malignancy in Asia, with nearly half of global gastric cancer deaths occurring in this region; China reports over 350,000 new cases and more than 260,000 deaths annually [1]. - The lack of effective treatment options for difficult-to-treat subtypes, such as diffuse gastric cancer, highlights the critical need for improved early screening and timely intervention [1].